Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry

Journal of Viral Hepatitis

Volumn 24, Issue 10, 2017, Pages 840-849

  Welzel, T M ^a   Hinrichsen, H ^b   Sarrazin, C ^a,c   Buggisch, P ^d   Baumgarten, A ^e   Christensen, S ^f   Berg, T ^g   Mauss, S ^h   Teuber, G ⁱ   Stein, K ^j   Deterding, K ^k   van Bommel F ^g   Heyne, R ^l   John, C ^m   Zimmermann, T ⁿ   Lutz, T ^o   Schott, E ^p   Hettinger, J ^q   Kleine, H ^q   Konig B ^q   Huppe D ^r   Wedemeyer, H ^k   more..

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c ST JOSEFS HOSPITAL   (Germany)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e Center for Infectiology (CIB)   (Germany)

^f Center for Interdisciplinary Medicine   (Germany)

^g UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^h Center for HIV and Hepatogastroenterology   (Germany)

ⁱ Hepatologie – Magdeburg ^*  (Germany)

^j Infect Dis   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l Leberzentrum Checkpoint   (Germany)

^m Practice for Internal Medicine/Cardiology   (Germany)

ⁿ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^o Infektiologikum   (Germany)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q ABBVIE INC   (United States)

^r Medical Office for Gastroenterology and Hepatology   (Germany)

more..

Author keywords

chronic hepatitis C; cirrhosis; dasabuvir; direct acting antivirals; ombitasvir paritaprevir r

Indexed keywords

DASABUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; ABT-267; ABT-333; ABT-450; ANILIDE; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; RITONAVIR; SULFONAMIDE; URACIL;

ABNORMAL LABORATORY RESULT; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INSOMNIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODERATE RENAL IMPAIRMENT; NAUSEA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SEVERE RENAL IMPAIRMENT; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VERY ELDERLY; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; GENOTYPE; GERMANY; HEPACIVIRUS; SEVERITY OF ILLNESS INDEX; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANILIDES; CARBAMATES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GERMANY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; RITONAVIR; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TREATMENT OUTCOME; URACIL; VIRAL LOAD;

EID: 85019708861     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12708     Document Type: Article

References (26)

1. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19:850-858.
2. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61:S58-S68.
3. Bruggmann P, Berg T, Øvrehus ALH, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;21(Suppl 1):5-33.
4. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA J Am Med Assoc. 2012;308:2584-2593.
5. Rehermann B. HCV in 2015: advances in hepatitis C research and treatment. Nat Rev Gastroenterol Hepatol. 2016;13:70-72.
6. AbbVie Ltd (United Kingdom). EU summary of product characteristics (Smpc), Viekirax® and Exviera®, 08/2016. 2016.
7. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594-1603.
8. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604-1614.
9. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983-1992.
10. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973-1982.
11. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359-365 e1.
12. Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2016;64:301-307.
13. Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502-2509.
14. Sarrazin C, Berg T, Buggisch P, et al. S3 guideline hepatitis C addendum. Z Gastroenterol 2015;53:320-334.
15. Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150:1590-1598.
16. Pogorzelska J, Flisiak R. Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection. J Clin Exp Hepatol. 2016;2:34-37.
17. Zuckerman E. The real-world Israeli experience of treating chronic hepatitis C, genotype 1 patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin: a large multi-center cohort [abstract PS004]. Int. Liver Conf. ILC 2016 Barc. Spain.
18. Calleja JL. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir and dasabuvir patients with genotype 1 chronic hepatitis C virus infection: results from the Spanish real world cohort [abstract LBP512]. Int. Liver Conf. ILC 2016 Barc. Spain
19. Teti E. Dasabuvir and ombitasvir/paritaprevir/ritonavir ± ribavirin in patients with HIV-HCV coinfection: real life interim analysis of an Italian multicentre compassionate use program [abstract SAT-147]. Int. Liver Conf. ILC 2016 Barc. Spain.
20. Flisiak R. Predictors of fast response to ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in real life AMBER study in genotype 1 and 4 HCV infected patients as a rationale for shortening of treatment [abstract SAT-252]. Int. Liver Conf. ILC 2016 Barc. Spain.
21. Derbala MF. Efficacy and safety of ombitasvir/paritaprevir/ritonavir, with or without ribavirin, in patients with HCV genotype 4 infection – real-world experience from Qatar [abstract SAT-220]. Int. Liver Conf. ILC 2016 Barc. Spain.
22. Fuchs M. Effectiveness of ledipasvir/sofosbuvir and ombitasvir/paritaprevir/ritonavir/dasabuvir in treatment-naive and -experienced U.S. veterans with genotype 1 hepatitis C infection [abstract SAT-216]. Int. Liver Conf. ILC 2016 Barc. Spain.
23. Lubel JS. Real world evaluation of Viekira Pak (ritonavir-boosted paritaprevir, ombitasvir and dasabuvir +/- ribavirin) in HCV genotype 1 targeting advanced liver disease (the REV1TAL study) [abstract SAT-182]. Int. Liver Conf. ILC 2016 Barc. Spain.
24. McGinnis J. Analysis of the impact of HIV co-infection on hepatitis C treatment effectiveness for patients using new direct-acting antivirals [abstract LBP514]. Int. Liver Conf. ILC 2016 Barc. Spain.
25. Sarrazin C. Effect of baseline resistance-associated variants on SVR with 3D regimen with and without RBV in GT1a and GT1b-infected patients [abstract LBP503]. Int. Liver Conf. ILC 2016 Barc. Spain.
26. Fried MW. Safety of ABT-450/ritonavir/ombitasvir + dasabuvir with or without ribavirin in HCV genotype 1-infected patients: results from phase 2 and 3 trials [abstract 1951]. Boston, MA: AASLD; 2014.